MNPR
Income statement / Annual
Last year (2023), Monopar Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Monopar Therapeutics Inc.'s net income was -$8.40 M.
See Monopar Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$5.60 M
|
$7.59 M
|
$6.49 M
|
$4.07 M
|
$1.97 M
|
$1.77 M
|
$15.44 M
|
$280,355.00
|
$101,487.00
|
| General & Administrative
Expenses |
$3.23 M
|
$2.95 M
|
$2.63 M
|
$2.44 M
|
$2.36 M
|
$1.63 M
|
$1.17 M
|
$912,474.00
|
$587,075.00
|
| Selling & Marketing
Expenses |
-$3.23 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$3.23 M
|
$2.95 M
|
$2.63 M
|
$2.44 M
|
$2.36 M
|
$1.63 M
|
$1.17 M
|
$912,474.00
|
$587,075.00
|
| Other Expenses |
-$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$14.50 M |
$0.00 |
$0.00 |
| Operating Expenses |
$8.83 M |
$10.54 M |
$9.13 M |
$6.51 M |
$4.32 M |
$3.40 M |
$16.60 M |
$1.19 M |
$688,562.00 |
| Cost And Expenses |
$8.83 M |
$10.54 M |
$9.13 M |
$6.51 M |
$4.32 M |
$3.40 M |
$16.60 M |
$1.19 M |
$688,562.00 |
| Interest Income |
$429.04 M |
$21,239.00 |
$24,024.00 |
$81,902.00 |
$98,887.00 |
$103,215.00 |
$48,255.00 |
$7,232.00 |
$1,251.00 |
| Interest Expense |
$0.00 |
-$21,239.00 |
$0.00 |
$0.00 |
$0.00 |
$103,215.00 |
$48,255.00 |
$7,232.00 |
$0.00 |
| Depreciation &
Amortization |
$8.83 M
|
$10.54 M
|
$9.13 M
|
$6.51 M
|
$4.32 M
|
$3.33 M
|
$2.10 M
|
$1.19 M
|
$688,562.00
|
| EBITDA |
$429,039.00
|
-$10.54 M
|
-$9.13 M
|
-$6.63 M
|
-$4.32 M
|
-$3.40 M
|
-$16.60 M
|
-$1.19 M
|
-$688,560.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$429,039.00
|
$21,239.00
|
$24,024.00
|
$204,302.00
|
$98,887.00
|
$103,215.00
|
$48,255.00
|
$7,232.00
|
$1,249.00
|
| Income Before Tax |
-$8.40 M |
-$10.52 M |
-$9.10 M |
-$6.30 M |
-$4.22 M |
-$3.30 M |
-$16.55 M |
-$1.19 M |
-$687,311.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$8,831.23 |
-$21,239.00 |
-$24,024.00 |
-$81,902.00 |
-$98,887.00 |
-$71,615.00 |
-$2.10 M |
$800.00 |
-$688,562.00 |
| Net Income |
-$8.40 M |
-$10.49 M |
-$9.08 M |
-$6.22 M |
-$4.13 M |
-$3.23 M |
-$16.55 M |
-$1.19 M |
-$687,311.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.04 |
-0.83 |
-0.73 |
-0.57 |
-0.39 |
-0.31 |
-1.59 |
-0.11 |
-0.0649 |
| EPS Diluted |
-3.04 |
-0.83 |
-0.73 |
-0.57 |
-0.39 |
-0.31 |
-1.59 |
-0.11 |
-0.0649 |
| Weighted Average Shares
Out |
$2.76 M
|
$12.72 M
|
$12.47 M
|
$10.96 M
|
$10.59 M
|
$10.42 M
|
$10.42 M
|
$10.42 M
|
$10.59 M
|
| Weighted Average Shares
Out Diluted |
$2.76 M
|
$12.72 M
|
$12.47 M
|
$10.96 M
|
$10.59 M
|
$10.42 M
|
$10.42 M
|
$10.42 M
|
$10.59 M
|
| Link |
|
|
|
|
|
|
|
|
|
